Max Yusem is an associate in the Litigation practice of Paul Hastings and is based in the firm’s New York office. His practice focuses on complex litigation with an emphasis on intellectual property matters in the fields of pharmaceuticals and biotechnology.
Mr. Yusem received his law degree, with honors, from George Washington University School of Law in 2013, where he served on the George Washington International Law Review. He earned a Bachelor of Arts from the Department of Psychological and Brain Sciences at Johns Hopkins University in 2008. Mr. Yusem is admitted to the New York State Bar.
- Paul Hastings Secures Win in First DNJ Zoom Hatch-Waxman Act Trial, Including Significant Ruling Rejecting Extension of Obviousness-Type Double Patenting Law - April 8th, 2021
- Takeaways from Paul Hastings’ Completion of the First Zoom Hatch-Waxman Act Trial in DNJ - October 7th, 2020
- Extension of Regulatory Approval Stay Helps Relieve Hatch-Waxman Time Pressure Caused by COVID-19 - April 27th, 2020
- Supreme Court Continues to Build Out Its Framework for Patent Eligibility in High-Tech and Life Sciences Sectors - July 21st, 2014
- Supreme Court Ruling in Alice v. CLS Bank Continues Framework for Patent Eligibility Set Forth in Mayo v. Prometheus - June 19th, 2014
- District of New Jersey Prevents Generic Challenger from Using Claim Construction as a Backdoor to Introduce Barred Invalidity Defense - June 16th, 2014
- Federal Circuit Clarifies That Foreseeability Does Not Preclude the Application of the Doctrine of Equivalents - February 20th, 2014
- Prometheus: A New Dawn for Biotech Patents - October 8th, 2012